## CoVPN COVID-19 Correlates Analysis

the CoVPN Biostatistics Team

 $March\ 05,\ 2021$ 

## Contents

1	Day	57 Univariate CoR: Cox Models of Risk	9
	1.1	Hazard ratios	ć
	1.2	Marginalized risk and controlled vaccine efficacy plots	1
2	Day	29 Univariate CoR: Cox Models of Risk	19
	2.1	Hazard ratios	19
	2.2	Marginalized risk and controlled vaccine efficacy plots	$2^{4}$

4 CONTENTS

## List of Tables

1.1	Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*	9
1.2	Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile $^*$ .	10
2.1	Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*	19
2.2	Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*.	20

6 LIST OF TABLES

## List of Figures

1.1	Forest plots of hazard ratios among baseline seronegative vaccine recipients and subgroups with 95% point-wise confidence intervals.	11
1.2	Forest plots of hazard ratios of Day 'r Day' binding Ab to spike markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals	12
1.3	Forest plots of hazard ratios of Day 'r Day' binding Ab to RBD markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals	12
1.4	Forest plots of hazard ratios of Day 'r Day' pseudo neut ID50 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.	13
1.5	Forest plots of hazard ratios of Day 'r Day' pseudo neut ID80 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.	13
1.6	Marginalized cumulative risk by Day 'r tp' as functions of Day 'r Day' markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands. The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 'r tp' and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.	15
1.7	Marginalized cumulative risk by Day 'r tp' as functions of Day 'r Day' markers above a threshold $(\geq s)$ among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 'r tp' and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.	16
1.8	Controlled VE with sensitivity analysis as functions of Day 'r Day' markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection	17

8 LIST OF FIGURES

1.9	Marginalized cumulative incidence rate curves for trichotomized Day 'r Day' markers among baseline seronegative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.	18
2.1	Forest plots of hazard ratios among baseline seronegative vaccine recipients and subgroups with 95% point-wise confidence intervals.	21
2.2	Forest plots of hazard ratios of Day 'r Day' binding Ab to spike markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals	22
2.3	Forest plots of hazard ratios of Day 'r Day' binding Ab to RBD markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals	22
2.4	Forest plots of hazard ratios of Day 'r Day' pseudo neut ID50 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.	23
2.5	Forest plots of hazard ratios of Day 'r Day' pseudo neut ID80 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.	23
2.6	Marginalized cumulative risk by Day 'r tp' as functions of Day 'r Day' markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands. The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 'r tp' and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.	25
2.7	Marginalized cumulative risk by Day 'r tp' as functions of Day 'r Day' markers above a threshold $(\geq s)$ among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 'r tp' and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection	26
2.8	Controlled VE with sensitivity analysis as functions of Day 'r Day' markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.	27
2.9	Marginalized cumulative incidence rate curves for trichotomized Day 'r Day' markers among baseline seronegative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.	28

## Chapter 1

# Day 57 Univariate CoR: Cox Models of Risk

The main regression model is the Cox proportional hazards model. All plots are made with Cox models fit unless specified otherwise.

## 1.1 Hazard ratios

Table 1.1: Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker\*

Mock	No. cases /	HR per 1	10-fold incr.	P-value	q-value	FWER
Immunologic Marker	No. at-risk**	Pt. Est.	95% CI	(2-sided)		
Spike IgG (IU/ml)	72/13,254	0.08	(0.05-0.12)	< 0.001	< 0.001	< 0.001
RBD IgG (IU/ml)	72/13,254	0.17	(0.12 - 0.25)	< 0.001	< 0.001	< 0.001
PsV-nAb ID50	72/13,254	0.24	(0.18 - 0.31)	< 0.001	< 0.001	< 0.001
PsV-nAb ID80	72/13,254	0.38	(0.28 - 0.51)	< 0.001	< 0.001	< 0.001

<sup>\*</sup>Baseline covariates adjusted for: age in years, at risk or not, community of color or not \*\*No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID at 7 days post Day 57 visit; no. cases = number of this cohort with an observed COVID endpoints.

Table 1.2: Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile\*


Mock	Tertile	No. cases /	Attack	Haz	. Ratio	P-value	Overall P-	Overall q-	Overall
Immunologic Marker		No. at-risk**	rate	Pt. Est.	95% CI	(2-sided)	value***	value	FWER
Spike IgG (IU/ml)	Lower	67/4,425	0.0151	1	N/A	N/A	< 0.001	< 0.001	< 0.001
	Middle	4/4,403	0.0009	0.04	(0.01-0.11)	< 0.001			
	Upper	$1/4,\!426$	0.0002	0.00	(0.00-0.03)	< 0.001			
RBD IgG (IU/ml)	Lower	45/4,437	0.0101	1	N/A	N/A	< 0.001	< 0.001	< 0.001
	Middle	19/4,398	0.0043	0.24	(0.13-0.43)	< 0.001			
	Upper	8/4,420	0.0018	0.05	(0.02 - 0.12)	< 0.001			
PsV-nAb ID50	Lower	56/4,443	0.0126	1	N/A	N/A	< 0.001	< 0.001	< 0.001
	Middle	9/4,382	0.0021	0.10	(0.05-0.22)	< 0.001			
	Upper	6/4,429	0.0014	0.05	(0.02 - 0.11)	< 0.001			
PsV-nAb ID80	Lower	40/4,434	0.0090	1	N/A	N/A	< 0.001	< 0.001	< 0.001
	Middle	21/4,400	0.0048	0.43	(0.24 - 0.79)	0.006			
	Upper	11/4,420	0.0025	0.17	(0.08 - 0.34)	< 0.001			
Placebo		713/13,271	0.0537						

<sup>\*</sup>Baseline covariates adjusted for: age in years, at risk or not, community of color or not . Average follow-up time 172 days, maximum follow-up time 185 days. Cutpoints: Spike IgG (IU/ml) [6.09, 6.7), RBD IgG (IU/ml) [5.68, 6.38), PsV-nAb ID50 [2.8, 3.66), PsV-nAb ID80 [3.08, 3.82) \*\*No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID at 7 days post Day 57 visit; no. cases = number of this cohort with an observed COVID endpoints. \*\*\*Generalized Wald-test p-value of the null hypothesis that the hazard rate is constant across the Lower, Middle, and Upper tertile groups.


### Binding Antibody to Spike: Day 57

Group	No. Ev	vents	HR (95% CI)
All baseline negative, vaccii	ne 72	+	0.08 (0.05, 0.12)
Age >= 65	37	-	0.10 (0.06, 0.17)
Age < 65, At risk	27	-	0.06 (0.03, 0.11)
Age < 65, Not at risk	8	-	0.01 (0.00, 0.06)
		0 02 04 06 08 1 12 14 16	18 2

#### Binding Antibody to RBD: Day 57



#### PsV Neutralization 50% Titer: Day 57






Figure 1.1: Forest plots of hazard ratios among baseline seronegative vaccine recipients and subgroups with 95% point-wise confidence intervals.

1.2 1.4 1.6

1.8

#### Group (Baseline Negative) No. Events HR (95% CI) All Vaccine 0.08 (0.05, 0.12) 72 Age >= 65 37 0.10 (0.06, 0.17) Age < 65 35 0.05 (0.03, 0.09) At risk 52 0.11 (0.07, 0.16) Not at risk 20 0.03 (0.01, 0.07) Comm. of color 28 0.10 (0.06, 0.18) White Non-Hispanic 44 0.06 (0.04, 0.11) Men 39 0.07 (0.04, 0.13) Women 33 0.07 (0.04, 0.14)

Binding Antibody to Spike: Day 57

Figure 1.2: Forest plots of hazard ratios of Day 'r Day' binding Ab to spike markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

Binding Antibody to RBD: Day 57

0.6 0.8

0.2 0.4

#### Group (Baseline Negative) No. Events HR (95% CI) All Vaccine 0.17 (0.12, 0.25) 72 Age >= 65 37 0.23 (0.15, 0.36) Age < 65 35 0.11 (0.07, 0.18) At risk 52 0.18 (0.12, 0.27) Not at risk 20 0.13 (0.07, 0.27) Comm. of color 28 0.21 (0.13, 0.33) White Non-Hispanic 44 0.15 (0.08, 0.26) Men 39 0.23 (0.15, 0.35) 0.11 (0.06, 0.22) Women 33 0.2 0.4 0.6 0.8 1.2 1.4 1.6 1.8

# Figure 1.3: Forest plots of hazard ratios of Day 'r Day' binding Ab to RBD markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

### PsV Neutralization 50% Titer: Day 57

Group (Baseline Negative	e) No. Eve	ents	HR (95% CI)
All Vaccine	72		0.24 (0.18, 0.31)
Age >= 65	37		0.25 (0.18, 0.36)
Age < 65	35		0.21 (0.14, 0.34)
At risk	52		0.25 (0.18, 0.34)
Not at risk	20	<del></del>	0.19 (0.10, 0.35)
Comm. of color	28	<del></del>	0.26 (0.18, 0.39)
White Non-Hispanic	44	<del></del>	0.21 (0.14, 0.32)
Men	39	<del></del>	0.21 (0.13, 0.33)
Women	33	<del></del>	0.27 (0.18, 0.39)
		0 02 04 06 08 1 12 14 1	16 19 2

Figure 1.4: Forest plots of hazard ratios of Day 'r Day' pseudo neut ID50 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

Group (Baseline Negative	/e) No. Even	ts	HR (95% CI)
All Vaccine	72	<del></del>	0.38 (0.28, 0.51)
Age >= 65	37	<del></del>	0.38 (0.25, 0.56)
Age < 65	35	<del></del>	0.39 (0.25, 0.61)
At risk	52	<del></del>	0.39 (0.27, 0.54)
Not at risk	20		0.38 (0.22, 0.66)
Comm. of color	28	<del></del>	0.32 (0.21, 0.48)
White Non-Hispanic	44		0.43 (0.28, 0.66)
Men	39	<del></del>	0.29 (0.18, 0.46)
Women	33		0.47 (0.32, 0.70)
		0 02 04 06 08 1 12 14 16 18	7

Figure 1.5: Forest plots of hazard ratios of Day 'r Day' pseudo neut ID80 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

1.2 Marginalized risk and controlled vaccine efficacy plots




Figure 1.6: Marginalized cumulative risk by Day 'r tp' as functions of Day 'r Day' markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands. The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 'r tp' and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.




Figure 1.7: Marginalized cumulative risk by Day 'r tp' as functions of Day 'r Day' markers above a threshold  $(\geq s)$  among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 'r tp' and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.




Figure 1.8: Controlled VE with sensitivity analysis as functions of Day 'r Day' markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.




Figure 1.9: Marginalized cumulative incidence rate curves for trichotomized Day 'r Day' markers among baseline seronegative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.

## Chapter 2

# Day 29 Univariate CoR: Cox Models of Risk

The main regression model is the Cox proportional hazards model. All plots are made with Cox models fit unless specified otherwise.

## 2.1 Hazard ratios

Table 2.1: Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker\*

Mock	No. cases /	HR per	10-fold incr.	P-value	q-value	FWER
Immunologic Marker	No. at-risk**	Pt. Est.	95% CI	(2-sided)		
Spike IgG (IU/ml)	83/13,271	0.09	(0.05 - 0.16)	< 0.001	< 0.001	< 0.001
RBD IgG (IU/ml)	83/13,271	0.25	(0.16 - 0.38)	< 0.001	< 0.001	< 0.001
PsV-nAb ID50	83/13,271	0.32	(0.23 - 0.46)	< 0.001	< 0.001	< 0.001
PsV-nAb ID80	83/13,271	0.57	(0.43 - 0.75)	< 0.001	< 0.001	< 0.001


<sup>\*</sup>Baseline covariates adjusted for: age in years, at risk or not, community of color or not \*\*No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID at 7 days post Day 29 visit; no. cases = number of this cohort with an observed COVID endpoints.

Table 2.2: Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile\*


Mock	Tertile	No. cases /	Attack	Haz	. Ratio	P-value	Overall P-	Overall q-	Overall
Immunologic Marker		No. at-risk**	rate	Pt. Est.	95% CI	(2-sided)	value***	value	FWER
Spike IgG (IU/ml)	Lower	54/4,422	0.0122	1	N/A	N/A	< 0.001	< 0.001	< 0.001
	Middle	24/4,423	0.0054	0.20	(0.11-0.37)	< 0.001			
	Upper	5/4,427	0.0011	0.02	(0.01 - 0.06)	< 0.001			
RBD IgG (IU/ml)	Lower	46/4,419	0.0104	1	N/A	N/A	< 0.001	< 0.001	< 0.001
	Middle	25/4,428	0.0056	0.30	(0.17 - 0.55)	< 0.001			
	Upper	12/4,424	0.0027	0.08	(0.04-0.17)	< 0.001			
PsV-nAb ID50	Lower	47/4,403	0.0107	1	N/A	N/A	< 0.001	< 0.001	< 0.001
	Middle	24/4,420	0.0054	0.33	(0.19 - 0.59)	< 0.001			
	Upper	12/4,448	0.0027	0.12	(0.06-0.25)	< 0.001			
PsV-nAb ID80	Lower	30/4,416	0.0068	1	N/A	N/A	0.001	< 0.001	< 0.001
	Middle	36/4,429	0.0081	0.94	(0.55-1.62)	0.834			
	Upper	17/4,426	0.0038	0.33	(0.17 - 0.64)	0.001			
Placebo		821/13,299	0.0617						

<sup>\*</sup>Baseline covariates adjusted for: age in years, at risk or not, community of color or not . Average follow-up time 200 days, maximum follow-up time 213 days. Cutpoints: Spike IgG (IU/ml) [4.38, 4.94), RBD IgG (IU/ml) [4.11, 4.66), PsV-nAb ID50 [1.67, 2.38), PsV-nAb ID80 [1.97, 2.64) \*\*No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID at 7 days post Day 29 visit; no. cases = number of this cohort with an observed COVID endpoints. \*\*\*Generalized Wald-test p-value of the null hypothesis that the hazard rate is constant across the Lower, Middle, and Upper tertile groups.


### Binding Antibody to Spike: Day 29



#### Binding Antibody to RBD: Day 29



#### PsV Neutralization 50% Titer: Day 29






Figure 2.1: Forest plots of hazard ratios among baseline seronegative vaccine recipients and subgroups with 95% point-wise confidence intervals.

1.2 1.4 1.6

1.8

#### Group (Baseline Negative) No. Events HR (95% CI) All Vaccine 0.09 (0.05, 0.16) 83 Age >= 65 40 0.08 (0.04, 0.16) Age < 65 43 0.07 (0.03, 0.18) At risk 0.10 (0.05, 0.18) 55 Not at risk 28 0.06 (0.02, 0.15) Comm. of color 32 0.12 (0.06, 0.26) White Non-Hispanic 51 0.07 (0.03, 0.15) Men 46 0.09 (0.04, 0.17) Women 37 0.09 (0.03, 0.22)

Binding Antibody to Spike: Day 29

# Figure 2.2: Forest plots of hazard ratios of Day 'r Day' binding Ab to spike markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

0.6 0.8

0.2 0.4

#### Group (Baseline Negative) No. Events HR (95% CI) All Vaccine 0.25 (0.16, 0.38) 83 Age >= 65 40 0.23 (0.12, 0.45) Age < 65 43 0.23 (0.13, 0.42) At risk 55 0.27 (0.17, 0.45) Not at risk 28 0.18 (0.09, 0.39) Comm. of color 32 0.27 (0.16, 0.48) White Non-Hispanic 51 0.24 (0.13, 0.43) Men 46 0.28 (0.17, 0.47) Women 37 0.20 (0.10, 0.43) 0.2 0.4 0.6 0.8 1.2 1.4 1.6 1.8

Binding Antibody to RBD: Day 29

# Figure 2.3: Forest plots of hazard ratios of Day 'r Day' binding Ab to RBD markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

#### PsV Neutralization 50% Titer: Day 29

Group (Baseline Negativ	e) No. Events	3	HR (95% CI)
All Vaccine	83	<del></del>	0.32 (0.23, 0.46)
Age >= 65	40	<del></del>	0.28 (0.17, 0.46)
Age < 65	43	<del></del>	0.36 (0.23, 0.57)
At risk	55	<del></del>	0.32 (0.21, 0.49)
Not at risk	28	<del></del>	0.33 (0.19, 0.57)
Comm. of color	32	<del></del>	0.40 (0.25, 0.65)
White Non-Hispanic	51	<del></del>	0.28 (0.17, 0.45)
Men	46	<del></del>	0.35 (0.22, 0.56)
Women	37		0.29 (0.17, 0.48)
			7
		0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8	2

Figure 2.4: Forest plots of hazard ratios of Day 'r Day' pseudo neut ID50 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

Group (Baseline Negative	e) No. Events		HR (95% CI)
All Vaccine	83	<del></del>	0.57 (0.43, 0.75)
Age >= 65	40	<del></del>	0.54 (0.35, 0.83)
Age < 65	43	<del></del>	0.57 (0.37, 0.85)
At risk	55	<del></del>	0.58 (0.42, 0.81)
Not at risk	28		0.50 (0.28, 0.92)
Comm. of color	32		0.67 (0.45, 1.01)
White Non-Hispanic	51	<del></del>	0.50 (0.34, 0.74)
Men	46	<del></del>	0.60 (0.42, 0.86)
Women	37		0.52 (0.33, 0.84)
	(	0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8	7

Figure 2.5: Forest plots of hazard ratios of Day 'r Day' pseudo neut ID80 markers among baseline seronegative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

2.2 Marginalized risk and controlled vaccine efficacy plots




Figure 2.6: Marginalized cumulative risk by Day 'r tp' as functions of Day 'r Day' markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands. The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 'r tp' and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.




Figure 2.7: Marginalized cumulative risk by Day 'r tp' as functions of Day 'r Day' markers above a threshold  $(\geq s)$  among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 'r tp' and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.




Figure 2.8: Controlled VE with sensitivity analysis as functions of Day 'r Day' markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands. Histograms of the immunological markers in the vaccine arm are overlaid. lod: lower limit of detection.




Figure 2.9: Marginalized cumulative incidence rate curves for trichotomized Day 'r Day' markers among baseline seronegative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.